US-based Enanta Pharmaceuticals Inc has raised $56m in its IPO. The company priced four million shares at $14 per share for an initial market cap of approximately $236 million.
Enanta Pharmaceuticals, a developer of drugs for infectious diseases backed by trade peers Shionogi and Abbott Labs, has raised $56m in its IPO from 4.6m shares priced at $14.00. JP Morgan and Credit Suisse served as co-lead underwriters .
Enanta reports $21m in net income on around $4m in revenue for 2012. Shareholders include TVM Life Science Ventures (18.76% pre-IPO stake), Saints Capital (15.68%), Shionogi & Co. (12.51%), Abbott Labs (8.38%), Industry Ventures (7.14%) and HBM Healthcare Investments (7.11%).
The…
